a restatement of the XTL Biopharmaceuticals Ltd. financial statements for the year ended December31, 2020, by way of an amendment to its previously false

אקס טי אל ביופרמסוטיקלס בע"מ	2 380
X T L BIOPHARMACEUTICALS LTD
Corporation no: 520039470	4313

	Israel Securities Authority			Tel Aviv Stock Exchange		C002 ( Public )		Reported via MAGNA:	19/05/2021
	www.isa.gov.il			www.tase.co.il				Reference:	2021-02-086931	Time of broadcast: 18:56 18:56

Immediate Report

Regulation 4 of the Securities Regulations, (Periodic and Immediate Reports of Foreign Corporation) 5761-2000

The corporation is a foreign private issuer as defined by U.S. Securities Laws.

Attached hereto is a report on

a restatement of the XTL Biopharmaceuticals Ltd. financial statements for the year ended December 31, 2020, by way of an amendment to its previously filed Form 20-F.

xtlbiopharmaEDGAR1_Bannerless_isa.pdf

References of previous documents relating to this matter(the reference does not constitute incorporation by reference):
Stock Exchange/Market: NASDAQ CM	Date of revision of form structure: 04/05/2021
Address: HaCharoshet st 5 , Ra'anana 43656   Israel , Tel: 09-9557080 , Fax: 09-9519708
E-mail address: ir@xtlbio.com   Company site: www.xtlbio.com
Previous names of reporting entity: XENOGRAFT TECHNOLOGIES LTD
Name of the Signatory: Kntor Ronen Position of Signatory in the reporting corporation: Attorney/Legal Counsel Name of Employer Company:
Address: abba hillel 12 , ramat gan 5250606 Telephone: 03-6133371 Facsimile: 03-6133372 E-mail: rkantor@dtkgc.com 1